When viability was assessed in a diverse panel of human cancer cell lines, it selectively inhibited the proliferation of BCR::ABL1 expressing leukemic cell lines but showed minimal or no effect on cells not expressing BCR::ABL1 [466]. The gene discussed is ABL1; the disease is cancer.